Botulinum toxin type A treatment of painful focal neuropathies: new evidence for efference of afferents.
Murinson
Beth B
BB
D000344:Afferent Pathways / Q000187:drug effects* / Q000502:physiology; D019274:Botulinum Toxins, Type A / Q000494:pharmacology*; D015740:Calcitonin Gene-Related Peptide / Q000378:metabolism; D004525:Efferent Pathways / Q000187:drug effects* / Q000502:physiology; D005089:Exocytosis / Q000187:drug effects / Q000502:physiology; D005727:Ganglia, Spinal / Q000187:drug effects / Q000378:metabolism; D018698:Glutamic Acid / Q000378:metabolism; D006801:Humans; D009437:Neuralgia / Q000188:drug therapy* / Q000503:physiopathology; D009465:Neuromuscular Agents / Q000494:pharmacology; D009619:Nociceptors / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D010525:Peripheral Nerves / Q000187:drug effects* / Q000503:physiopathology; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy* / Q000503:physiopathology
D009465:Neuromuscular Agents; D018698:Glutamic Acid; D019274:Botulinum Toxins, Type A; D015740:Calcitonin Gene-Related Peptide